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Quality Assessment of a Collaborative Approach
for Decreasing Drug-Related Morbidity
and Achieving Therapeutic Goals
Brian J. Isetts, PhD, BCPS; Lawrence M. Brown, PharmD;
Stephen W. Schondelmeyer, PharmD, PhD; Lois A. Lenarz, MD
Background: Collaboration between physicians and
pharmacists is one approach to address drug-relatedmor-
bidity and achieve therapeutic goals. A collaborative prac-
tice of pharmaceutical care has been used in the Fair-
view Clinics System of Minneapolis-St Paul since 1999.
Methods: The quality of therapeutic determinations
made by pharmacists within this collaborative practice
of pharmaceutical carewas studied by a 12-member panel
of physicians and pharmacists who used randomly se-
lected patient records. This was a quality improvement
and care process validation component of a study evalu-
ating the effects of drug therapy management in pa-
tients receiving prepaid medical assistance. An implicit
review process was used to evaluate the clinical credibil-
ity of therapeutic determinations made by pharmaceu-
tical care practitioners.
Results:A total of 5780 drug therapy problems were re-
solved for 2524 patients receiving pharmaceutical care.
The rate of therapeutic goals achieved increased from74%
at the time of patients’ initial pharmaceutical care en-
counters to 89% at patients’ latest encounters. In this qual-
ity assessment analysis panel members performed a total
of 4779 evaluations of clinical decisions. Panelists indi-
cated agreement with the evaluations in 94.2% of cases,
expressed a neutral opinion in 3.6% of cases, and dis-
agreed in 2.2% of cases. Intraclass correlation coeffi-
cients ranged from 0.73 to 0.85.
Conclusions:Thedecisionsmade by pharmaceutical care
practitioners working in collaboration with physicians
to provide drug therapy management services are clini-
cally credible based on the evaluations and comments of
a peer review panel. This study provides information on
the quality of care provided by pharmacists when col-
laborating with physicians to provide drug therapyman-
agement services.
Arch Intern Med. 2003;163:1813-1820
P ATIENT SAFETY and qualityimprovement in the UShealth care systemhave beenthe focus of national re-ports.1,2 These reports have
called for redesigning the health care sys-
tem from the perspective of optimizing re-
sponsiveness to patients’ needs.When the
needs are related to the use of medica-
tions, patients benefit from collaborative
efforts between physicians and pharma-
cists toward achieving intended goals of
drug therapy while avoiding or minimiz-
ing adverse consequences. Several meth-
ods of effective collaboration in drug
therapy management have been de-
scribed.3-5
The collaboration between physi-
cians and pharmacists addresses undesir-
able and ineffective consequences ofmedi-
cation use. “Drug misadventuring” and
“drug-related morbidity and mortality”
have been used to describe such conse-
quences.6-8 Studies of drug-related mor-
bidity and mortality have focused on the
incidence of adverse drug events and drug
complications,9-12 characteristics of hos-
pital readmissions,13 and preventabil-
ity.9,14 In 1995, the cost impact of these
drug therapy problems in the US health
care system was estimated at $76 billion,
and updated to $177 billion for 2000.8,15
Causes of drug-relatedmorbidity andmor-
tality include acts of commission (ie, pre-
scribing and dispensing drugs, and ad-
ministering errors), idiosyncratic causes
(ie, unpredictable medication conse-
quences), and acts of omission (ie, ab-
sence of systems designed to consistently
help patients achieve desired therapeutic
goalswhile avoiding orminimizing the ad-
verse consequences ofmedication use). Al-
though various risk factors have been as-
sociated with complications from drug
therapy,16-19 the predictive validity of risk
factors for such problems needs further
study.Undesirablemedication-related con-
sequences are not necessarily the fault of
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any individual, and they do not constitute a special field
of medicine. Rather, they represent a need to apply theo-
ries and approaches already used in other fields to mini-
mize adverse consequences and improve reliability.1
Pharmacists working in collaboration with physi-
cians through a redesigned approach to medication use
can prevent errors and reduce drug costs.20 One of 4 re-
cent suggestions for improving the quality of medica-
tion use in elderly patients includes a call for enhanced
collaboration between those who prescribe drugs and
those who know drugs best, ie, clinical pharmacists.21 In
a 2-year study of 397 patients with low- or high-risk coro-
nary heart disease whose pharmacists and physicians
worked persistently and collaboratively to promote ad-
herence with prescribed dyslipidemic therapy, it was
found that, at their last full lipid profile, 62.5% of pa-
tients were at or below the low-density lipoprotein cho-
lesterol target levels specified by the National Choles-
terol Education Program.22
Drug therapy management and drug management
are terms used in proposed federal legislation and in fed-
eral government reports to describe contemporary mod-
els in which pharmacists and physicians work together
tomanage the complexmedicationneeds ofMedicare ben-
eficiaries. A report released by theMedicare Payment Ad-
visory Commission states that “drug management is an
evolving approach to care in which drug therapy deci-
sions are coordinated collaboratively by physicians, phar-
macists and other health professionals together with the
patient.” The Medicare Payment Advisory Commission
report also recommends that the Secretary of the US De-
partment of Health and Human Services assess models
for collaborative drug therapy management services in
outpatient settings.23
The impact of pharmacists’ contributions to drug
therapy decisionmaking is found in the literature evalu-
ating the effectiveness of clinical pharmacy services.24,25
A Cochrane database review examining the effects of ex-
panding the roles of ambulatory pharmacists on patient
outcomes and health care use suggests that pharmacist
intervention can improve patient behavior and adher-
ence and improve physician prescribing.26 Studies of phar-
macists’ performance in clinical decision making re-
lated to the use of medications include a description of
decision-making models,27 factors influencing drug
therapy decision making by pharmacists,28 and decision
analysis applied to clinical pharmacy.29
The term pharmaceutical care was described in the
literature in 1975 as pertaining to the care that a given
patient requires and receives which assures safe and ra-
tional drug usage.18,30 An article published in 1990 ar-
ticulated the responsibilities of a pharmaceutical care prac-
titioner desiring to expand beneficial drug therapy
management services, including the creation of a cov-
enantal bond or therapeutic relationship between pa-
tient and pharmacist.31 The practice of pharmaceutical
care is now defined as “a practice in which the practi-
tioner takes responsibility for all of a patient’s drug-
related needs and is held accountable for this commit-
ment.”18
A consistent and systematic pharmaceutical care pro-
cess is used to (1) assess all of a patient’s drug-related
needs, identify drug therapy problems, and establish thera-
peutic goals; (2) design a pharmaceutical care plan to help
the patient achieve the established goals and resolve or
prevent drug therapy problems; and (3) conduct fol-
low-up evaluationswith the patient to determine progress
toward these goals. A drug therapy problem is defined
as “any aspect of a patient’s drug therapy that is inter-
fering with a desired, positive patient outcome.”18 A clas-
sification of drug therapy problems is presented in
Table 1. The practice of pharmaceutical care outlined
in this article encompasses drug therapymanagement de-
scribed in proposed federal legislation as well as federal
government reports; therefore, the termdrug therapyman-
agement is used synonymouslywithpharmaceutical care.23
PEER REVIEW
Peer review has been used as a quality improvement strat-
egy in medicine and nursing.32,33 In contrast to explicit
review, which requires strict predetermined criteria that
ignore extenuating circumstances, implicit review inte-
grates all available information about each patient.34 Re-
searchers working in conjunction with the RAND Cor-
poration created a structured implicit review (SIR) process
for assessing the quality of medical care delivered in the
hospital and ambulatory care settings.32 The SIR pro-
cess guides the reviewer through medical records infor-
mation and allows for a more consistent review of care
delivered.
A SIR process relevant to the practice of pharma-
ceutical care was used for this analysis based upon the
RAND SIR process. The use of SIR has been central to
Medicare qualitymanagement and for reviewing care de-
livered by physicians. Reviewers apply their profes-
sional expertise to provide implicit judgments about the
quality of care delivered by individual clinicians.35 Al-
though implicit review often has high face validity, poor
interrater reliability is often a drawback. Assessments
based on medical record reviews, especially when im-
plicit and not guided by objective criteria, can produce
disagreement among physicians on the appropriateness
and quality of care delivered to specific patients.36
The intraclass correlation coefficient (ICC) has been
used to measure interrater reliability within the implicit
review process. Six different intraclass correlation mod-
els have been delineated based on the selection of pa-
tients and reviewers, and on whether the goal is to com-
Table 1. Classification of Drug Therapy Problems*
Indication
1. Additional drug therapy needed
2. Unnecessary drug therapy being used
Effectiveness
3. Ineffective drug therapy
4. Dosage too low
Safety
5. Adverse drug reaction
6. Dosage too high
Convenience
7. Adherence to therapy
*Adapted from Cipolle et al.18
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pare individual raters with other raters or with the mean
rating of all raters.37 Coefficients above 0.75 indicate ex-
cellent agreement, those from 0.40 to 0.75 indicate fair
to good agreement, and those below 0.40 indicate poor
agreement.38
One study on the quality of medical care found that,
when using SIRs, outcome measures had higher inter-
rater reliability thanprocessmeasures.39 In pharmacy, peer
review has been applied primarily in the institutional set-
ting as part of continuous quality improvement efforts
to evaluate, validate, and improve the appropriateness of
pharmacists’ clinical interventions.40 In this study, peer
review by physicians and pharmacists was performed to
evaluate interventions of pharmaceutical care practition-
ers intending to identify and resolve drug therapy prob-
lems and achieve the therapeutic goals of patients in an
ambulatory health care setting.
PROGRAM ORGANIZATION
Collaboration to provide drug therapymanagement ser-
vices exists at 6 of the largest clinics within the Fairview
Clinics System of Minneapolis-St Paul, Minn, and more
than 3000 patients have received drug therapy manage-
ment services since the program inception in 1999. There
were 3195 patients in active pharmaceutical care plans
throughFebruary 2003.Drug therapymanagementwithin
the Fairview system is defined as “a practice in which a
credentiated pharmaceutical care practitioner, working
in collaboration with physicians and other care-givers,
takes responsibility for all of a patient’s drug-related needs
and is held accountable for this commitment.”
Pharmacists complete a 120-hour, 8-week, 50-
patient certificate preparation program in pharmaceuti-
cal care provided by the Peters Institute of Pharmaceuti-
cal Care at the University of Minnesota. This program
represents a paradigm shift for pharmacists. It focuses on
a unique philosophy of practice and process of care, and
prepares generalist practitioners to identify, resolve, and
prevent drug therapy problems. This preparation pro-
gramcontrastswith continuing educationprogramsondis-
ease state management or certification programs by the
Board of Pharmaceutical Specialties, because the empha-
sis of these latter programs is on content areas or clinical
knowledge. Three pharmaceutical care practitioners in the
Fairview systemholddoctorate degrees inpharmacy, 3oth-
ers hold bachelors’ degrees in pharmacy, and their total
experience as pharmacists ranges between 3 and 21 years
(mean, 12 years). Two pharmacists completed postgradu-
ate residency programs, and 1 is a Board-Certified Phar-
macotherapy Specialist.
The Fairview Credentialing Committee comprises
9 physicians and 1 pharmaceutical care practitioner who
accredit pharmaceutical care practitioners to provide care
in the Fairview system. Physicians and pharmaceutical
care practitioners use a collaborative practice agree-
ment to enhance cooperation in the delivery of drug
therapy management services. Patients schedule phar-
maceutical care appointments pursuant to physician re-
ferrals, informational mailings, self-referrals, and health
insurance company notifications. Pharmaceutical care
practitioners conduct patient assessments in a clinic ex-
amination room or in a semiprivate pharmacy consulta-
tion area.
Fairview’s pharmaceutical care practitioners assess
and document actual therapeutic outcomes at every pa-
tient encounter using a pharmaceutical care software
documentation program (Assurance PharmaceuticalCare;
licensed by the University of Minnesota, Minneapolis).
Consistent with the collaborative practice agreement, a
set of therapeutic goals are established for each of a pa-
tient’s medical conditions during the initial stage of care
plan development. These are clinical goals established in
the literature, combined with realistic, observable, and
measurable patient-specific goals. Occasionally, pre-
scriber, pharmacist, and patientmay confer to discuss pa-
tient expectations or goals of therapy.
After each encounter, a pharmaceutical care docu-
mentation note is entered into the patient’s medical rec-
ord. The note includes the intended use and dose of all
active prescription andover-the-countermedications, plus
a summary of the outcome of therapy. If the patient is
experiencing a potentially harmful or urgent drug therapy
problem, the pharmaceutical care practitioners inter-
vene immediately through consultation with the pa-
tient’s physician(s).
All patients seen in the 6 Fairview clinics affiliated
with a pharmaceutical care practitioner are eligible to re-
ceive pharmaceutical care services regardless of ability
to pay or health insurance status. Patients in the Fair-
view system receive these services through various re-
search grants, demonstration projects, and third-party
payer pilot programs, or as part of a central Fairview De-
partment of Pharmacy health system budget.
METHODS
PHARMACEUTICAL CASE SIR
A SIR process was developed as a component in the assess-
ment of the quality improvement of Fairview’s pharmaceuti-
cal care, and to provide information on the validity of thera-
peutic determinationsmadebypharmaceutical care practitioners.
Information was obtained on the reliability of this pharmaceu-
tical care SIR process. Validity in this analysis refers to the face
validity, or clinical credibility, of the determinationsmadewhen
collaborating to provide drug therapy management services.
Records for panel reviewwere drawn from those of a group
of patients receiving pharmaceutical care as part of a grant de-
signed to study the effects of providing drug therapy manage-
ment services to prepaid medical assistance program (PMAP)
patients. A total of 142 PMAP patients had at least 2 visits with
a pharmaceutical care practitioner between January 1, 2000,
and December 31, 2000. The University of Minnesota’s Re-
search Subjects Protection Program reviewed and approved this
study.
REVIEW PANEL PROCESS
Fifteen of the 142 PMAP patient records were randomly se-
lected for peer review as case records. A 12-member peer re-
view panel was assembled, consisting of 4 physicians with pa-
tients in pharmaceutical care plans, 4 physicianswith no patients
in pharmaceutical care plans (they were practicing at a Fair-
view clinic that had no pharmaceutical care practitioner), and
4 pharmaceutical care practitioners. Physician panel members
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were selected for the reviewpanel in consultationwith theMedi-
cal Director of Fairview Clinics based on their previous expe-
riences serving on peer review panels. Pharmaceutical care prac-
titioners were selected based on their seniority in Fairview’s
Pharmaceutical Care Program. Each panelist evaluated 5 case
records, and each set of case records were evaluated by 4 pan-
elists. Panelists were compensated for their time and they did
not evaluate cases in which they had provided care.
The patient case records included copies of the medical
record and pharmaceutical care chart but were devoid of any
patient, clinic, or provider identifiers. The 4 therapeutic deter-
minations evaluated by panelists were (1) drug therapy prob-
lem determinations in the presence or absence of drug therapy
problems; (2) actions taken to resolve drug therapy problems;
(3) clinical condition status, including progress toward achiev-
ing goals of therapy; and (4) short-term cost savings esti-
mates, if any, related to the resolution of drug therapy prob-
lems. Each line item, or situation, on the pharmaceutical care
SIR research instrument consisted of amedical condition, amedi-
cation, directions for use of the medication, and the 4 thera-
peutic determinations. If a patient was taking a second medi-
cation for a givenmedical condition, this represented a distinct
line item, or situation, on the research instrument. A situation
also included a medical condition not being treated or a treat-
ment with no indication.
VALIDITY
Each therapeutic determinationwas rated using a 7-point Likert
scale, with a rating of 1 corresponding to “strongly disagree”
and a rating of 7 corresponding to “strongly agree.” A Likert
rating from 5 to 7 was considered an agreement, a rating of 4
was considered a neutral opinion, and a rating of 1 to 3 was
considered a disagreement. Panelists using a rating of 1 to 4
on any item (ie, strongly disagree through neutral opinion)were
encouraged to include a comment describing the reason(s) for
their rating. When either 3 or 4 of the four panelists reviewing
a given situation agreed with the pharmaceutical care practi-
tioners’ determination, that determinationwas considered valid
or clinically credible.
RELIABILITY
To obtain information on the reliability of the pharmaceutical
care SIR process, 3 sets of 2 patient records were selected to be
reviewed by the same 4 panelists. Patients 3 and 4 were re-
viewed by panelists 4, 6, 8, and 11 (set 1); patients 7 and 8were
reviewed by panelists 1, 6, 9, and 10 (set 2); and patients 13
and 14 were reviewed by panelists 3, 5, 7, and 12 (set 3). An
ICC 3, 4was then calculated for the 3 sets of 2 patient cases—an
ICC 3, 4 indicates (1) that patients were randomly selected, (2)
that 4 reviewers were purposively selected per patient, and (3)
that each reviewer’s scores were compared with themean score
for all 4 reviewers who reviewed a given set of patient cases.
RESULTS
PATIENT DEMOGRAPHICS
There were 5810 documented encounters with 2524 pa-
tients in active pharmaceutical care plans from January
1999 throughMarch 2002, or an average of 2.3 visits per
patient. The patients ranged in age from 3 to 97 years,
48% of them were older than 65 years, and 66% were
women. These 2524 patients had among them a total of
16406medical conditions (an average of 6.5medical con-
ditions per patient) present at both their initial and lat-
est pharmaceutical care encounters. They were taking,
on average, 8.2 active medications (Table 2). Demo-
graphic characteristics of the 142 PMAP patients receiv-
ing pharmaceutical care and the 15 peer-reviewed pa-
tients are also presented in Table 2.
RESOLVED DRUG THERAPY PROBLEMS
A total of 5897 drug therapy problems were identified
and resolved among the 2524 patients in Fairview’s Phar-
maceutical Care Program. For a problem to be consid-
ered resolved, therapy had to be changed based on the
pharmaceutical care practitioner’s recommendation, as
evidenced by a change in the physician’s order or in the
patient’s behavior. The distribution of the 5897 re-
solved drug therapy problems is presented in Table 3;
71% of them were resolved without the direct involve-
ment of the patient’s physician(s) while 29% were re-
solved with the active involvement of the patients’
physician(s).
A total of 259 drug therapy problems were re-
solved among the 142 PMAP patients enrolled in this
study, and 37 drug therapy problems were resolved in
Table 2. Characteristics of Patients
in Pharmaceutical Care Plans*
Characteristic
All Patients
(N = 2524)
PMAP Patients
(n = 142)
Peer-Reviewed
Patients
(n = 15)
No. of visits per patient,
mean
2.3 2.1 2.3
Age, range, y 3-97 18-96 32-73
Age 65 y, % 48 38 20
Female sex, % 66 76 80
No. of conditions per
patient, mean
6.5 6.6 6.2
No. of medications per
patient, mean
8.2 7.8 8.3
Abbreviation: PMAP, prepaid medical assistance program.
*Data collected from January 1999 through March 2002.
Table 3. Characteristics of Resolved
Drug Therapy Problems*
Characteristic
All
Patients
(N = 2524)
PMAP
Patients
(n = 142)
Peer-Reviewed
Patients
(n = 15)
Need for additional therapy 1720 (29) 85 (33) 19 (51)
Dosage too low 1266 (22) 60 (23) 3 (8)
Adherence 1045 (18) 34 (13) 3 (8)
Adverse drug reaction 692 (12) 33 (13) 3 (8)
Ineffective drug therapy 466 (8) 19 (7) 4 (11)
Unnecessary drug therapy 375 (6) 17 (7) 3 (8)
Dosage too high 333 (5) 11 (4) 2 (6)
DTPs identified and
resolved
5897 (100) 259 (100) 37 (100)
DTPs requiring physician
intervention, %
29 32 35
Abbreviations: DTPs, drug therapy problems; PMAP, prepaid medical
assistance program.
*Data are number (percentage) of patients unless otherwise indicated.
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the 15 peer-reviewed patients (Table 3). The 5 most fre-
quently encountered drug therapy problems by condi-
tion in the 142 PMAPpatientswere in the following order:
Condition/Indication Drug Therapy Problem
1. Osteoporosis Patient needs additional drug therapy
2. Asthma Patient is using medication incorrectly
3. Nutritional supplementation Patient needs additional drug therapy
4. Hypertension Adverse drug reaction
5. Hypothyroidism Dosage too low
The most frequently encountered drug therapy prob-
lems by condition in the 15 peer-reviewed patients were
in the following order:
Condition/Indication Drug Therapy Problem
1. Diabetes Patient needs additional drug therapy
2. Hypertension Patient needs additional drug therapy
3. Asthma Patient is using medication incorrectly
4. Gastroesophageal reflux disease Ineffective drug therapy
5. Nutritional supplementation No medical indication for use
GOALS OF THERAPY ACHIEVED
At the time of the 2524 patients’ first pharmaceutical care
visit, 74% of their therapeutic goals were being met. At
the time of their final pharmaceutical care encounter, 89%
of their therapeutic goals were met (Table 4). The goals
of therapy achieved in the 142 PMAP patients and the
15 peer-reviewed patients are also presented in Table 4.
REVIEW PANEL RESULTS
The 15 patient records randomly selected for this qual-
ity assessment analysis presented a total of 300 situa-
tions. As already explained, on the research instrument
each line item, or situation, consisted of a medical con-
dition, a medication, directions for use of the medica-
tion, and the 4 therapeutic determinations. This analy-
sis focused on the determinations made by the
pharmaceutical care practitioner regarding each of these
situations. Among the 300 situations, 37 showed a de-
termination of an identified drug therapy problem and
263 showed a determination that there was no drug
therapy problem present.
There were 300 situations with 4 types of determi-
nations reviewed by 4 different panel members, result-
ing in a total of 4800 reviews, or clinical decision evalu-
ations. Because the reviewers left the rating scale blank
for 21 determinations, the 12-member review panel gen-
erated 4779 clinical decision evaluations. The panelists’
ratings for 4500 of these evaluations (94.2%) agreed or
strongly agreed with the pharmaceutical care practition-
ers’ therapeutic outcome determinations. A neutral opin-
ionwas expressed in 172 instances (3.6%), and therewere
107 instances (2.2%) in which the panelists expressed
disagreement.
Ratingswere grouped to categorize the level of agree-
ment as follows: “agree” (a rating of 5-7), “neutral” (a rat-
ing of 4), and “disagree” (a rating of 1-3). The number and
distribution of agreement scores by type of determination
made was compiled (Table 5). The level of agreement
across reviewers and situations is presented in Table 6.
A valid or clinically credible level of agreement was found
for 97.9% (1175/1200) of the situations reviewed.
Panelists provided 300 comments describing the rea-
sons for their ratings. Of this total, 119 were general sup-
portive comments in conjunction with agreement rat-
ings and 93 were offered in conjunction with neutral
opinions. The panelists’ remaining 88 comments were of-
fered in conjunction with disagreement ratings of 1 to 3
on the Likert scale. The disagreement scores and corre-
sponding comments were fed back to the pharmaceuti-
cal care practitioners at monthly quality assurance case
presentation meetings to foster continuous quality im-
provement in clinical care.
RELIABILITY MEASUREMENTS
To obtain information on the reliability of this pharma-
ceutical care SIR process, 3 sets of 2 patient cases were
selected for review by the same 4 reviewers (ICC 3, 4).
For set 1 (patients 3 and 4 reviewed by panelists 4, 6, 8,
and 11), there was an ICC of 0.85. For set 2 (patients 7
and 8 reviewed by panelists 1, 6, 9, and 10), there was
an ICC of 0.75. For set 3 (patients 13 and 14 reviewed
by panelists 3, 5, 7, and 12), there was an ICC of 0.73.
ANALYSIS OF DRUG THERAPY PROBLEM
DETERMINATIONS
An analysis of the level of agreement related to the 37 drug
therapy problems identified in the 15 patients selected for
inclusion in this peer review analysiswas conducted to ob-
tain informationon the ability of pharmaceutical care prac-
titioners to correctly identify a drug therapy problem that
has been judged to exist. There was valid agreement for
100% (37/37) of the situations with drug therapy prob-
lems (Table 6). Unanimous agreement by all 4 panelists
was present for 28 of 37 drug therapy problem cases. In 7
of the 9 remaining cases 1 panelist expressed a neutral rat-
Table 4. Goals of Therapy Achieved Through Collaboration in Drug Therapy Management
Total No. of
Medical Conditions
Goals Met at Earliest DTM
Encounter, No. (%)
Goals Met at Latest DTM
Encounter, No. (%)
Percentage Point
Increase in Goals
Met, %
16 406 (In all 2524 patients) 12 141 (74) 14 609 (89) 15
937 (In the 142 PMAP patients) 733 (78) 841 (90) 12
93 (In the 15 peer-reviewed patients) 63 (68) 78 (84) 16
Abbreviations: DTM, drug therapy management; PMAP, prepaid medical assistance program.
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ing, and in the other 2 cases 1 reviewer disagreed. The 2
cases with disagreement were not related to the presence
of a drug therapy problem but with the classification of a
drug therapy problem (Table 1).
An analysis of the 263 situations determined to have
no drug therapy problems was conducted to provide in-
formation on the practitioners’ accuracy in stating that
no drug therapy problem exists (Table 6). There were
Table 5. Peer Review Panel Validity Ratings of Pharmaceutical Care Practitioner Therapeutic Determinations*
Therapeutic Outcome
Determinations
Reviews,
No.
% of Reviews by Rating
Agree Neutral Disagree Total†
All situations
Drug therapy problem (DTP) identification 1196 92.1 4.4 3.4 100.0
Action to resolve problem 1194 94.6 3.4 2.1 100.0
Condition status evaluation 1195 94.7 3.6 1.7 100.0
Estimate of cost savings 1194 95.2 3.0 1.8 100.0
All Determinations 4779 94.2 3.6 2.2 100.0
Situations with DTP
DTP identification 148 93.9 4.7 1.4 100.0
Action to resolve problem 148 95.9 2.7 1.4 100.0
Condition status evaluation 148 93.9 4.1 2.0 100.0
Estimate of cost savings 147 91.8 5.4 2.7 100.0
All Determinations 591 93.9 4.2 1.9 100.0
Situations without DTP
Absence of DTP 1048 91.9 4.4 3.7 100.0
Action to prevent problem 1046 94.4 3.4 2.2 100.0
Condition status evaluation 1047 94.8 3.5 1.6 100.0
Estimate of cost savings 1047 95.7 2.7 1.6 100.0
All Determinations 4188 94.2 3.5 2.3 100.0
*Validity refers to the face validity or clinical credibility of the determinations made during the collaborative practice of pharmaceutical care. Ratings were made
on a 7-point Likert scale, with 1=“strongly disagree” and 7=“strongly agree”; ratings of 1 to 3 were grouped as “disagree,” 4 as “neutral,” and 5 to 7 as “agree.”
†Of the total 4800 ratings, 21 were left blank by review panel members.
Table 6. Peer Review Panel Agreement on Validity Ratings of Pharmaceutical Care
Practitioner Therapeutic Outcome Determinations*
Therapeutic Outcome
Determinations
Situations
Reviewed, No.
% of Situations Reviewed by Level of Agreement
Agreement† on Validity Nonagreement† on Validity
All 4
Agree
3 Agree,
1 Neutral
3 Agree,
1 Disagree
Total
Agreement
Situations
2 Agree,
2 Neutral
2 Agree,
1 Neutral,
1 Disagree
Total
Nonagreement
Situations
All situations
Drug therapy problem (DTP)
identification
300 72.3 11.0 13.7 97.0 1.0 2.0 3.0
Action to resolve problem 300 80.3 9.7 8.0 98.0 0.7 1.3 2.0
Condition status evaluation 300 81.3 10.3 6.7 98.3 0.7 1.0 1.7
Estimate of cost savings 300 82.7 8.3 7.3 98.3 0.7 1.0 1.7
All Determinations 1200 79.2 9.8 8.9 97.9 0.8 1.3 2.1
Situations with DTP
DTP identification 37 75.7 18.9 5.4 100.0 0.0 0.0 0.0
Action to resolve problem 37 83.8 10.8 5.4 100.0 0.0 0.0 0.0
Condition status evaluation 37 78.4 10.8 10.8 100.0 0.0 0.0 0.0
Estimate of cost savings 37 73.0 10.8 10.8 94.6 2.7 2.7 5.4
All Determinations 148 77.7 12.8 8.1 98.6 0.7 0.7 1.4
Situations without DTP
DTP identification 263 71.9 9.9 14.8 96.6 1.1 2.3 3.4
Action to resolve problem 263 79.8 9.5 8.4 97.7 0.8 1.5 2.3
Condition status evaluation 263 81.7 10.3 6.1 98.1 0.8 1.1 1.9
Estimate of cost savings 263 84.0 8.0 6.8 98.8 0.4 0.8 1.2
All Determinations 1052 79.4 9.4 9.0 97.8 0.8 1.4 2.2
*Validity refers to the face validity or clinical credibility of the determinations made during the collaborative practice of pharmaceutical care. Ratings were made
on a 7-point Likert scale with 1 = “strongly disagree” and 7 = “strongly agree”; ratings of 1 to 3 were grouped as “disagree,” 4 as “neutral,” and 5 to 7 as “agree.”
†Each determination was reviewed by 4 reviewers and the agreement among reviewers was considered “valid and credible” when all 4 reviewers agreed; when
3 agreed and 1 was neutral; or when 3 agreed and 1 disagreed. Disagreement was determined by fewer than 3 reviewers rating “agree.” Note that the worst case
vote was 2 agree with 1 neutral and 1 disagree. In no case was there a vote with more disagree votes than agree votes.
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48 instances in which 1 of 4 panelists registered a dis-
agreement score when the pharmacist had determined
that there was no drug therapy problem. In 39 of these
48 instances, the other 3 panelists agreed with the phar-
macist’s determination. Therewere also 9 instanceswhere
2 reviewers were not in agreement with a determination
of no drug therapy problem. The pharmacist’s determi-
nation of the absence of a drug therapy problemwas there-
fore considered accurate for 96.6% of the situations
(254/263).
COMMENT
The results of this study suggest that decisions made by
pharmaceutical care practitioners working in collabora-
tion with physicians and other caregivers to provide drug
therapy management services are clinically credible. The
collaborative practice of pharmaceutical care may help to
reducedrug-relatedmorbidity and improve therapeuticout-
comes by optimizing responsiveness to patient needs in
their use of medication. Causes of suboptimal medica-
tion use outcomes include acts of commission, unpredict-
able events, and the absence of pharmaceutical care sys-
tems. The presence of a pharmaceutical care practitioner
who is responsible for applying a systematic problem-
solving process to the use of all of a patient’s medications
can consistently ensure that thepatients’ drug-relatedneeds
are met.
Recent studies and reviews suggest that pharma-
cists’ interventions can improve patient outcomes, re-
duce health expenditures, and prevent errors. The im-
pact of pharmacists’ contributions in drug therapydecision
making is found in the literature evaluating the effec-
tiveness of clinical pharmacy services. Compared with
studies of pharmacists’ performance in clinical decision
making, this study provides information relating to the
face validity or clinical credibility of collaborative drug
therapy management services.
Although there are indications that the pharmaceu-
tical care SIR process used in this analysis is reliable us-
ing the ICC in a subset of common patient cases, addi-
tional studies would help to corroborate these findings.
This was discovery work, conducted to identify trends
and patterns of agreementwith pharmaceutical care prac-
titioners’ therapeutic determinations using an implicit re-
view process. Further studies in this area could be de-
signed to have all panelists review the same patient cases
to test the reliability of rater measurements and com-
pare ratings between individual panelists.
The main responsibilities of pharmaceutical care
practitioners are to identify, resolve, and prevent drug
therapy problems that impede progress toward achiev-
ing intended therapeutic goals. A quality improvement
analysis of drug therapy problemdeterminationswas con-
ducted to obtain information on practitioners’ abilities
to identify a drug therapy problem when one is judged
to exist, and to accurately state that no drug therapy prob-
lem exists. This analysis revealed estimates of 100% ac-
curacy in identifying drug therapy problems and 97% in
determining the absence of drug therapy problems.
Documenting patients’ actual therapeutic out-
comes represents a desirable activity in any health care
system. Therapeutic goals achieved increased from 74%
at the time of patients’ initial pharmaceutical care en-
counters to 89% at their latest encounters. This study pro-
vides data demonstrating the clinical credibility of the
therapeutic outcome determinations of pharmaceutical
care practitioners when they collaborate with physi-
cians to provide drug therapy management services.
Patients, health care providers, employers, third-party pay-
ers, and policymakers can use these data to make better-
informed decisions about the value and role of collabo-
ration in reducing drug-relatedmorbidity and achieving
therapeutic goals.
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Correction
Incorrect Name Order. In the Commentary by Goodnough et al titled “Ane-
mia: Not Just an Innocent Bystander?” published in the June 23 issue of the
ARCHIVES (2003;163:1400-1404), the authors should have appeared in the fol-
lowing order in the signature block on page 1403: Lawrence T. Goodnough
MD; Robert W. Dubois, MD, PhD; and Allen R. Nissenson, MD. The journal
regrets the error.
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